Cargando…
Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States
BACKGROUND: The objective of this study was to characterize hospitalized coronavirus disease 2019 (COVID-19) patients and describe their real-world treatment patterns and outcomes over time. METHODS: Adult patients hospitalized on May 1, 2020–December 31, 2020 with a discharge diagnosis of COVID-19...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522394/ https://www.ncbi.nlm.nih.gov/pubmed/34984212 http://dx.doi.org/10.1093/ofid/ofab498 |
_version_ | 1784585080178475008 |
---|---|
author | Mozaffari, Essy Chandak, Aastha Zhang, Zhiji Liang, Shuting Gayle, Julie Thrun, Mark Gottlieb, Robert L Kuritzkes, Daniel R Sax, Paul E Wohl, David A Casciano, Roman Hodgkins, Paul Haubrich, Richard |
author_facet | Mozaffari, Essy Chandak, Aastha Zhang, Zhiji Liang, Shuting Gayle, Julie Thrun, Mark Gottlieb, Robert L Kuritzkes, Daniel R Sax, Paul E Wohl, David A Casciano, Roman Hodgkins, Paul Haubrich, Richard |
author_sort | Mozaffari, Essy |
collection | PubMed |
description | BACKGROUND: The objective of this study was to characterize hospitalized coronavirus disease 2019 (COVID-19) patients and describe their real-world treatment patterns and outcomes over time. METHODS: Adult patients hospitalized on May 1, 2020–December 31, 2020 with a discharge diagnosis of COVID-19 were identified from the Premier Healthcare Database. Patient and hospital characteristics, treatments, baseline severity based on oxygen support, length of stay (LOS), intensive care unit (ICU) utilization, and mortality were examined. RESULTS: The study included 295657 patients (847 hospitals), with median age of 66 (interquartile range, 54–77) years. Among each set of demographic comparators, the majority were male, white, and over 65. Approximately 85% had no supplemental oxygen charges (NSOc) or low-flow oxygen (LFO) at baseline, whereas 75% received no more than NSOc or LFO as maximal oxygen support at any time during hospitalization. Remdesivir (RDV) and corticosteroid treatment utilization increased over time. By December, 50% were receiving RDV and 80% were receiving corticosteroids. A higher proportion initiated COVID-19 treatments within 2 days of hospitalization in December versus May (RDV, 87% vs 40%; corticosteroids, 93% vs 62%; convalescent plasma, 68% vs 26%). There was a shift toward initiating RDV in patients on NSOc or LFO (68.0% [May] vs 83.1% [December]). Median LOS decreased over time. Overall mortality was 13.5% and it was highest for severe patients (invasive mechanical ventilation/extracorporeal membrane oxygenation [IMV/ECMO], 53.7%; high-flow oxygen/noninvasive ventilation [HFO/NIV], 32.2%; LFO, 11.7%; NSOc, 7.3%). The ICU use decreased, whereas mortality decreased for NSOc and LFO. CONCLUSIONS: Clinical management of COVID-19 is rapidly evolving. This large observational study found that use of evidence-based treatments increased from May to December 2020, whereas improvement in outcomes occurred over this time-period. |
format | Online Article Text |
id | pubmed-8522394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85223942021-10-20 Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States Mozaffari, Essy Chandak, Aastha Zhang, Zhiji Liang, Shuting Gayle, Julie Thrun, Mark Gottlieb, Robert L Kuritzkes, Daniel R Sax, Paul E Wohl, David A Casciano, Roman Hodgkins, Paul Haubrich, Richard Open Forum Infect Dis Major Articles BACKGROUND: The objective of this study was to characterize hospitalized coronavirus disease 2019 (COVID-19) patients and describe their real-world treatment patterns and outcomes over time. METHODS: Adult patients hospitalized on May 1, 2020–December 31, 2020 with a discharge diagnosis of COVID-19 were identified from the Premier Healthcare Database. Patient and hospital characteristics, treatments, baseline severity based on oxygen support, length of stay (LOS), intensive care unit (ICU) utilization, and mortality were examined. RESULTS: The study included 295657 patients (847 hospitals), with median age of 66 (interquartile range, 54–77) years. Among each set of demographic comparators, the majority were male, white, and over 65. Approximately 85% had no supplemental oxygen charges (NSOc) or low-flow oxygen (LFO) at baseline, whereas 75% received no more than NSOc or LFO as maximal oxygen support at any time during hospitalization. Remdesivir (RDV) and corticosteroid treatment utilization increased over time. By December, 50% were receiving RDV and 80% were receiving corticosteroids. A higher proportion initiated COVID-19 treatments within 2 days of hospitalization in December versus May (RDV, 87% vs 40%; corticosteroids, 93% vs 62%; convalescent plasma, 68% vs 26%). There was a shift toward initiating RDV in patients on NSOc or LFO (68.0% [May] vs 83.1% [December]). Median LOS decreased over time. Overall mortality was 13.5% and it was highest for severe patients (invasive mechanical ventilation/extracorporeal membrane oxygenation [IMV/ECMO], 53.7%; high-flow oxygen/noninvasive ventilation [HFO/NIV], 32.2%; LFO, 11.7%; NSOc, 7.3%). The ICU use decreased, whereas mortality decreased for NSOc and LFO. CONCLUSIONS: Clinical management of COVID-19 is rapidly evolving. This large observational study found that use of evidence-based treatments increased from May to December 2020, whereas improvement in outcomes occurred over this time-period. Oxford University Press 2021-09-28 /pmc/articles/PMC8522394/ /pubmed/34984212 http://dx.doi.org/10.1093/ofid/ofab498 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Articles Mozaffari, Essy Chandak, Aastha Zhang, Zhiji Liang, Shuting Gayle, Julie Thrun, Mark Gottlieb, Robert L Kuritzkes, Daniel R Sax, Paul E Wohl, David A Casciano, Roman Hodgkins, Paul Haubrich, Richard Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States |
title | Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States |
title_full | Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States |
title_fullStr | Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States |
title_full_unstemmed | Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States |
title_short | Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States |
title_sort | clinical management of hospitalized coronavirus disease 2019 patients in the united states |
topic | Major Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522394/ https://www.ncbi.nlm.nih.gov/pubmed/34984212 http://dx.doi.org/10.1093/ofid/ofab498 |
work_keys_str_mv | AT mozaffariessy clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT chandakaastha clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT zhangzhiji clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT liangshuting clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT gaylejulie clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT thrunmark clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT gottliebrobertl clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT kuritzkesdanielr clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT saxpaule clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT wohldavida clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT cascianoroman clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT hodgkinspaul clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates AT haubrichrichard clinicalmanagementofhospitalizedcoronavirusdisease2019patientsintheunitedstates |